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Abstract
OBJECTIVES: Perhexiline is thought to modulate metabolism by inhibiting mitochondrial carnitine palmitoyltransferase-1, reducing fatty
acid uptake and increasing carbohydrate utilization. This study assessed whether preoperative perhexiline improves markers of myocardial
protection in patients undergoing coronary artery bypass graft surgery and analysed its effect on the myocardial metabolome.
METHODS: In a prospective, randomized, double-blind, placebo-controlled trial, patients at two centres were randomized to receive either
oral perhexiline or placebo for at least 5 days prior to surgery. The primary outcome was a low cardiac output episode in the first 6 h. All
pre-specified analyses were conducted according to the intention-to-treat principle with a statistical power of 90% to detect a relative risk of
0.5 and a conventional one-sided α-value of 0.025. A subset of pre-ischaemic left ventricular biopsies was analysed using mass spectrometry-
based metabolomics.
RESULTS: Over a 3-year period, 286 patients were randomized, received the intervention and were included in the analysis. The incidence
rate of a low cardiac output episode in the perhexiline arm was 36.7% (51/139) vs 34.7% (51/147) in the control arm [odds ratio (OR) 0.92,
95% confidence interval (CI) 0.56–1.50, P = 0.74]. Perhexiline was associated with a reduction in the cardiac index at 6 h [difference in means
0.19, 95% CI 0.07–0.31, P = 0.001] and an increase in inotropic support in the first 12 h (OR 0.55, 95% CI 0.34–0.89, P = 0.015). There were no
significant differences in myocardial injury with troponin-T or electrocardiogram, reoperation, renal dysfunction or length of stay. No differ-
ence in the preischaemic left ventricular metabolism was identified between groups on metabolomics analysis.
CONCLUSIONS: Preoperative perhexiline does not improve myocardial protection in patients undergoing coronary surgery and in fact
reduced perioperative cardiac output, increasing the need for inotropic support. Perhexiline has no significant effect on the mass spectrom-
etry-visible polar myocardial metabolome in vivo in humans, supporting the suggestion that it acts via a pathway that is independent of myo-
cardial carnitine palmitoyltransferase inhibition and may explain the lack of clinical benefit observed following surgery.
ClinicalTrials.Gov ID: NCT00845364.
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INTRODUCTION
The population of patients undergoing cardiac surgery is becom-
ing older, with more comorbidities and complex patterns of
disease, requiring more urgent surgery [1]. Such factors are often
associated with abnormal myocardial metabolism and may con-
tribute towards increasing the length of ischaemic arrest, which
remains an independent predictor of mortality in contemporary
practice [2]. With current techniques for myocardial protection
using blood cardioplegia, up to 30% of patients have a period of
clinically detectable transient dysfunction due to myocardial stun-
ning. An episode of non-fatal low cardiac output in the early post-
operative period is associated with a significant reduction in late
survival following coronary artery bypass graft (CABG) surgery [3]
and inadequate protection may lead to permanent injury due to
diffuse necrosis, fibrosis, remodelling and long-term impairment
of ventricular function. The need for longer periods of ischaemia
in more metabolically vulnerable patients necessitates further re-
search to improve protection strategies [4].
Pharmacological manipulation of myocardial metabolism aims
to induce a shift in substrate utilization from fatty acids to glucose,
thereby increasing energy efficiency and decreasing the potential-
ly harmful effects of β-oxidation. Suppression of fatty acid utiliza-
tion improves coupling of glycolysis to glucose oxidation, reduces
lactate production, diminishes mitochondrial proton leakage and
increases the efficiency of adenosine triphosphate (ATP) produc-
tion per mole of oxygen [5]. Metabolic drugs may have a role in
myocardial protection as adjuncts to cardioplegia and hypother-
mia by increasing metabolic efficiency and reducing the impact of
ischaemia–reperfusion injury, thereby translating into enhanced
recovery of cardiac function during reperfusion, and improved
clinical outcomes. We have previously shown that glucose–insulin–
potassium (GIK) therapy improves myocardial protection in patients
with multivessel disease undergoing CABG [6] and in those with left
ventricular hypertrophy undergoing aortic valve replacement [7].
However, GIK therapy has not been widely adopted due to the lack
of large multicentre randomized, controlled trials or a standardized
protocol, increased monitoring requirements with high-dose insulin,
the potential negative impact of perioperative hyperglycaemia and
uncertainty over its mechanisms of action. An agent with a similar
metabolic efficacy but without the complexity of administration is
desirable although the evidence of benefit for such an agent in
myocardial protection is lacking.
Perhexiline is a modulator of myocardial metabolism that is ef-
fective in patients with refractory angina unsuitable for revascular-
ization [8] and chronic cardiac failure [9, 10]. However, marked
interindividual variation in its metabolism via cytochrome p450
2D6 (CYP2D6) previously resulted in severe adverse events due to
chronic toxicity in a small number of poor metabolizers; toxicity
can be prevented by therapeutic drug monitoring and dose ad-
justment to achieve plasma concentrations within the therapeutic
range (0.15–0.6 mg/l) [11]. In the rat heart, it has been shown to
inhibit carnitine palmitoyltransferase-1 (CPT-1), the key uptake
enzyme for long-chain fatty acids into mitochondria, and this is
thought to be its primary mechanism of action [12]. We report a
prospective, double-blind, randomized, placebo-controlled trial
to investigate whether preoperative administration of oral per-
hexiline improves clinical markers of myocardial protection in
patients undergoing CABG at two centres in the UK. To examine
the impact of perhexiline on myocardial metabolism in humans,
we analysed the polar metabolic profile of left ventricular biopsies
obtained prior to ischaemia from patients within the therapeutic
range for perhexiline compared with controls using high-
resolution mass spectrometry (MS) [13]. The polar metabolome
was chosen to provide the greatest insight into energy metabol-
ism, including glycolysis and the citric acid cycle.
MATERIALS ANDMETHODS
Study design
A prospective, two-centre, double-blind, randomized, placebo-
controlled trial of preoperative perhexiline (PEXSIG, Aspen Australia,
Croydon, Victoria, Australia) was conducted in patients undergoing
elective or urgent (during the same hospital admission) isolated,
first-time CABG for multivessel coronary artery disease. The study
was approved by the Cambridgeshire 1 Research Ethics Committee
(06/Q0104/41) and the Medicines and Healthcare products
Regulatory Agency (2006-003164-62). The trial was registered with
ClinicalTrials.gov (NCT00845364), and patients were enrolled
between February 2007 and April 2010 at the Queen Elizabeth
Hospital Birmingham and the Royal Sussex County Hospital,
Brighton, UK. Informed consent was obtained from each participant
and all research was performed in accordance with the Declaration
of Helsinki and the UK Human Tissue Act 2004 within a research
governance framework.
The exclusion criteria were diabetes mellitus, significant renal or
hepatic impairment, peripheral neuropathy, porphyria, atrial fibrilla-
tion, recent amiodarone therapy, emergency surgery (before the
next scheduled operating list), known hypersensitivity to perhexiline
or prospectively identified as requiring a significant deviation from
the protocol on clinical grounds. Patients were randomized to
either perhexiline or placebo in a 1 : 1 ratio using a computer-
generated random allocation sequence with minimization for
surgeon, priority of surgery and left ventricular function. All tablets
were identical in appearance to conceal allocation. Trial medication
was commenced a minimum of 5 days prior to the planned date of
surgery and continued for up to 31 days. A standardized loading
and maintenance regime was used: 200 mg b.i.d. for 3 days fol-
lowed by 100 mg b.i.d. until the morning of surgery. Blood was
drawn prior to anaesthesia and stored; serum perhexiline concen-
trations were determined by high-performance liquid chromatog-
raphy at the end of the trial.
Surgery, anaesthesia, cardiopulmonary bypass
and myocardial protection
Anaesthesia, cardiopulmonary bypass (CPB) and myocardial protec-
tion with intermittent anterograde cardioplegia using St Thomas’ solu-
tion buffered in cold blood were all standardized as previously
described [6], except that phenylepherine was used as the first-line
vasoconstrictor. Distal anastomoses were performed during cardio-
plegic arrest and proximal anastomoses during partial aortic occlu-
sion. A pulmonary artery catheter was used to assess haemodynamic
variables, and the thermodilution technique was used to measure
cardiac function. Baseline haemodynamic studies were performed
prior to sternotomy. Following weaning from CPB, further measure-
ments were taken before and 10 min after the administration of
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cross-clamp. Standardized protocols were used to guide perioperative
management including heart rate, volume expansion, inotrope use,
temperature and glycaemic control. Serial blood samples were drawn
at baseline at 6, 12 and 24 h to determine troponin-T by ECLIA
(Roche Diagnostics, Burgess Hill, UK) and plasma non-esterified free
fatty acids by enzymatic colorimetric assay (Wako Chemicals, Neuss,
Germany).
End-points
The primary end-point was the incidence of a low cardiac output
episode (LCOE), defined as a cardiac index of <2.2 l/min/m2 re-
fractory to appropriate intravascular volume expansion after cor-
rection of dysrhythmias in the first 6 h after cross-clamp release. A
blinded end-points committee assessed all episodes of LCOE and
a consensus opinion was reached. A planned exploratory analysis
compared patients in the perhexiline arm who reached the lower
threshold of the therapeutic range (0.15 mg/l) with propensity
score-matched controls.
Secondary end-points were a comparison of cardiac index and
inotropic support in the first six and 12 h, peak and area under the
concentration–time curve (AUC) for troponin-T in the first 24 h
and perioperative myocardial injury on 12-lead electrocardiogram
(ECG). ECG changes were assessed by an independent blinded
cardiologist and defined as new Q waves ≥2 mm in two or more
contiguous leads, new bundle branch block or loss of R wave
progression by the 4th postoperative day.
Metabolomic analysis
Transmural biopsies of the left ventricular free wall between the
left anterior descending artery and the first diagonal branch were
obtained prior to application of the aortic cross-clamp and imme-
diately snap-frozen. Metabolites were extracted using a methanol
: water : chloroform solvent system [14], dried using a centrifugal
concentrator and stored at −80°C. Subsequently, each dried polar
extract was re-dissolved in 80 : 20 methanol:water containing 20
mM ammonium acetate, vortexed and centrifuged prior to MS.
Quality control (QC) samples were prepared by pooling an aliquot
of each sample.
MS analyses were conducted using a hybrid 7-Tesla linear ion trap
Fourier transform ion cyclotron resonance (FT-ICR) MS (LTQ FT Ultra,
Thermo Fisher Scientific, Germany) equipped with a Triversa chip-
based nano-electrospray ion source (Advion Biosciences, NY, USA)
using conditions as described previously [15]. Three mass spectra
for each sample were collected using a selected-ion-monitoring
stitching method fromm/z (mass-to-charge ratio) 70–740 in negative
ion mode [15, 16], processed, normalized and generalized log-
transformed as reported previously [17, 18]. This produced a peak in-
tensity matrix representing the metabolic profile of each extracted
biopsy. Using the MI-Pack software [19], m/z measurements were
putatively annotated (see Supplementary material).
Statistical analysis
Clinical trial. All analyses were prespecified and conducted
according to the intention-to-treat principle. The trial had a
statistical power of 90% to identify a relative risk of 0.50, which was
statistically significant, assuming an incidence of LCOE in the
control group of 0.37 and a conventional one-sided α of 0.025.
Analyses were conducted with SAS software version 9.1 or above
(SAS Institute, Inc., Cary, NC, USA). Continuous data are presented as
mean (standard deviation, SD) or median (interquartile range, IQR).
P-values other than for the primary end-point were nominal. All
analyses were stratified for left ventricular function and urgency of
surgery as patient-level covariates, and surgeon as a random effect.
Dichotomous outcomes were analysed with the use of nonlinear
mixed models and continuous data with mixed models. Propensity
scoring approaches were used to identify matched controls, based
on age, race, weight, days of trial therapy, left ventricular function
and priority of surgery. Supportive analyses were conducted using
generalized linear models and repeated measures.
Metabolomics. Student’s t-tests were conducted on the
non-generalized log-transformed peak intensity matrix, using a false
discovery rate (FDR) of 5%, to determine if individual peaks changed
significantly between groups [20]. In addition, principal components
analyses (PCA) and partial least squares-discriminant analyses
(PLS-DA) were conducted to discover metabolic differences between
groups. Internal cross-validation was applied to assess for over-fitting
of the optimal PLS-DAmodel.
Additional methods appears in the Supplementary material.
RESULTS
Study population
Three hundred and twenty-seven patients were randomized of
whom 286 were included in the analysis (Fig. 1), 139 randomized
to perhexiline and 147 to placebo (see Supplementary material).
Baseline preoperative characteristics were similar between the
groups (Table 1) including median logistic EuroSCORE: 1.82 (1.23–
3.06) in the treatment arm and 1.82 (1.07–2.94) in the control arm.
Participants took the trial medication for a median of 10 days (6–
12 days) prior to surgery. Eighteen (6.3%) patients reported poten-
tial side effects of perhexiline, principally nausea or dizziness, of
whom 15 were in the treatment group and three in the placebo
group; 6 (4.3%) patients in the perhexiline group reported non-
compliance with the dosing protocol due to side effects. Serum
perhexiline at the time of surgery was measured in 280 patients
including 135/139 (97.1%) in the treatment group in whom the
median serum concentration was 0.24 mg/l (0.33 mg/l) with a
range of 0.04–1.97 mg/l. In the perhexiline arm, 37 (27.4%)
patients were below the lower threshold of the therapeutic range
(0.15 mg/l); there was no correlation between serum perhexiline
level and length of therapy. In the placebo group, all patients mea-
sured had a serum perhexiline level of zero, confirming the differ-
ence between the groups.
All patients underwent multivessel CABG. One patient in the per-
hexiline and 3 in the control group had an additional mitral valve
procedure and 1 further patient in the control group underwent
aortic valve replacement. Operative variables including CPB and
aortic cross-clamp times were similar between groups (Table 2).
Primary outcome
A LCOE was diagnosed in 102 of 286 (35.7%) patients analysed;
however, there was no significant difference in incidence between
the two groups: 51/139 (36.7%) in the perhexiline arm and 51/147
(34.7%) in the control arm (OR 0.92, 95% CI 0.56–1.50, P = 0.74)
(Table 3). In the exploratory analysis, patients in the perhexiline arm
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who were above the lower threshold of the therapeutic range
(≥0.15 mg/l) at the time of surgery were compared with propensity
score-matched controls (n = 97 in each group, 1 patient excluded
due to missing data). There remained no significant difference in the
incidence of LCOE between groups: 38/97 (39.2%) for perhexiline
and 31/97 (32.0%) for controls (OR 0.73, 95% CI 0.40–1.33, P = 0.30).
Secondary outcomes
Haemodynamic data. At 6 h following reperfusion, the mean
cardiac index was significantly lower in the perhexiline group (2.51
l/min/m2, SD 0.43) than in the control group (2.70 l/min/m2, SD
0.54) (difference in means 0.19, 95% CI 0.07–0.31, P = 0.001) (Fig. 2).
By 12 h after reperfusion, there was no difference between the
groups: 2.73 l/min/m2 (SD 0.54) for perhexiline vs 2.79 l/min/m2
(SD 0.48) for controls (difference in means 0.058, 95% CI −0.06–
0.18, P = 0.34). Throughout the study, heart rate, mean arterial
pressure, central venous pressure and pulmonary artery wedge
pressure were similar between groups.
Cardiac index measured prior to ischaemia was found to be sig-
nificantly lower in the perhexiline group (2.09 l/min/m2, SD 0.57)
than in the control group (2.31 l/min/m2, SD 0.53) (difference in
means 0.22, 95% CI 0.09–0.35, P = 0.001). Using repeated measures,
the cardiac index was found to be significantly affected by perhexi-
line therapy (difference in means 0.13, 95% CI 0.08–0.17, P < .0001).
Inotrope and vasoconstrictor use. There was no difference in
the prevalence of inotropic support in the first 6 h after
reperfusion: perhexiline 39/139 (28.1%) vs control 36/147 (24.5%)
(OR 0.84, 95% CI 0.49–1.44, P = 0.52). However, by 12 h, inotrope
use was significantly more frequent in the perhexiline group (67/
139, 48.2%) versus the control group (50/147, 34.0%) (OR 0.55,
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95% CI 0.34–0.89, P = 0.015). There were no differences between
groups in the dose requirements for phenylepherine (P = 0.26),
norepinephrine (P = 0.12) or insulin (P = 0.43) in the first 12 h.
Myocardial injury. There was no difference in the mean peak
serum troponin-T concentration during the first 24 h after surgery:
0.78 ng/ml (SD 0.71) in perhexiline patients vs 0.89 ng/ml (SD
0.92) in control patients (difference in means 0.11, 95% CI −0.09–
0.30, P = 0.28). The AUC in the first 24 h was also not significantly
different between groups: perhexiline 3.98 ng h/ml (SD 3.79) vs
control 4.71 ng h/ml (SD 5.32) (P = 0.12) (Fig. 3). There was no
difference in the frequency of ECG changes consistent with new
myocardial injury: 23/139 (16.6%) in the perhexiline group vs 25/
147 (17.0%) in the control group (OR 1.02, 95% CI 0.55–1.92,
P = 0.94).
Plasma non-esterified free fatty acids were measured in 35
patients (perhexiline n = 16, control n = 19) and found to be sig-
nificantly higher prior to ischaemia in the perhexiline group (0.75
mmol/l, SD 0.08) than in the control group (0.50 mmol/l, SD 0.13)
(P < 0.001). This difference was lost by 6 h into reperfusion: 0.73
mmol/l (SD 0.15) in the perhexiline group vs 0.70 mmol/l (SD
0.21) in the control group (P = 0.64). No significant relationship
between plasma free fatty acid concentration and pre-ischaemic
cardiac index was observed on regression (R2 = 0.09, P = 0.08).
There were no significant differences in the prespecified safety
end-points of death, stroke, the need for renal replacement
therapy, reoperation or length of ICU or hospital stay between
groups (Table 4).
Metabolomic analysis
Polar extracts from preischaemic left ventricular biopsies were
analysed from 43 patients (perhexiline n = 22, control n = 21). All
biopsies from the perhexiline group were from patients above the
lower end of the therapeutic range (median 0.36 mg/l, IQR 0.24–
0.58). The median spectral relative standard deviation, a bench-
mark to assess the reproducibility in metabolomics [21], for each
sample analysed in triplicate by MS was relatively small and con-
sistent across all samples (mean 11.6%, SD 1.6%). The final inten-
sity matrix after data processing consisted of 4039 peak intensity
measurements for each sample. All peaks were examined using
univariate statistics to determine if any intensity changed signifi-
cantly in response to perhexiline treatment. No significant peak
intensity changes were found (FDR 5%). Multivariate PCA was
used to reduce the dimensionality of the data and visualize the
metabolic similarities and differences between the two groups;
the plot of PCA scores did not show any metabolic effects due to
perhexiline treatment (Fig. 4). The clustering of the QC samples
demonstrates the consistency in instrument performance over
time. Additionally, PLS-DA was conducted to maximize the separ-
ation of the metabolic profiles of the two groups (see
Supplementary material). The control and treatment samples
were minimally separated, and the associated mean classification
error rates of the model for predicting class membership were
high at 43 and 47%, respectively, suggesting no metabolic differ-
ences between groups. More than 200 m/z measurements in the
FT-ICR MS dataset were assigned to at least one putative named
metabolite including ATP, creatine, phosphocreatine, glycolytic
and citric acid cycle intermediates (see Supplementary material).
DISCUSSION
In this double-blind, randomized, placebo-controlled trial of pre-
operative oral perhexiline as an adjunct to cold blood cardioplegia
for myocardial protection during CABG, there was no effect on
the primary end-point, the incidence of a LCOE. This was con-
firmed in a propensity score-matched analysis in which patients in
the treatment group who were below the therapeutic range were
excluded. In addition, there was no difference in the use of





Age, median (IQR) (years) 66.1 (59.4–73.2) 65.7 (60.2–73.6)
Male gender, n (%) 128 (92.1) 134 (91.2)
Race, n (%)
Caucasian 133 (95.7) 136 (92.5)
South Asian 5 (3.6) 10 (6.8)
Black 1 (0.7) 1 (0.7)
CCS class, n (%)
0 12 (8.6) 7 (4.8)
I 9 (6.5) 14 (9.5)
II 70 (50.4) 71 (48.3)
III 39 (28.1) 43 (29.3)
IV 9 (6.5) 12 (8.2)
NYHA class, n (%)
I 58 (41.7) 59 (40.1)
II 68 (48.9) 79 (53.7)
III 13 (9.4) 9 (6.1)
IV 0 (0) 0 (0)
Previous MI, n (%) 49 (35.3) 48 (32.7)
Previous coronary stent,
n (%)
13 (9.4) 10 (6.8)
Left main stem disease
≥50%, n (%)
54 (38.9) 47 (32.0)
Left ventricle function, n (%)
Good 118 (84.9) 122 (83.0)
Moderate 20 (14.4) 24 (16.3)
Poor 1 (0.7) 1 (0.7)
Priority, n (%)
Elective 120 (86.3) 124 (84.4)
Urgent 19 (13.7) 23 (15.7)
Smoker, n (%)
Non 38 (27.3) 55 (37.4)
Current 14 (10.1) 16 (10.9)
Ex-smoker 87 (62.6) 76 (51.7)
Pulmonary disease, n (%) 17 (12.2) 12 (8.2)
Peripheral vascular disease,
n (%)
14 (10.1) 10 (6.8)
Recent MI (last 90 days),
n (%)
19 (13.7) 17 (11.6)
Number of antianginal agents, n (%)
0 3 (2.2) 2 (1.4)
1 68 (48.9) 65 (44.2)
2 48 (34.5) 55 (37.4)
3 15 (10.8) 19 (12.9)
4 5 (3.6) 6 (4.1)
Haemoglobin, mean (SD)
(g/dl)
14.32 (1.3) 14.11 (1.2)
Creatinine, mean (SD)
(mg/dl)
1.20 (0.2) 1.12 (0.2)
EuroSCORE, median (IQR) 3 (1 to 4) 3 (1 to 4)
Logistic EuroSCORE,
median (IQR)
1.82 (1.23 to 3.06) 1.82 (1.07 to 2.94)
CCS: Canadian Cardiovascular Society; NYHA: New York Heart
Association; MI: myocardial infarction; SD: standard deviation; IQR:
interquartile range.
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inotropes in the first 6 h or the incidence of myocardial injury
determined by troponin release or significant ECG changes
between groups. Indeed, cardiac index was found to be lower in
the treatment arm compared with controls both prior to ischae-
mia and at 6 h after release of the aortic cross-clamp. On studying
the polar metabolome of the left ventricle prior to ischaemia
using MS-based metabolomics, we found that the metabolic pro-
files of patients on perhexiline, with confirmed therapeutic
plasma levels, were indistinguishable from those in the placebo
group.
Metabolic therapy provides an opportunity to improve myocar-
dial protection by inducing a shift in substrate utilization from
fatty acids to glucose, thereby increasing the efficiency of energy
production and reducing the harmful effects of β-oxidation during
reperfusion [4]. The most extensively studied metabolic strategy is
altering the availability and use of substrates using intravenous
GIK solution. Insulin has multiple metabolic and non-metabolic
effects on the myocardium but their relative importance is unclear.
These include suppression of lipolysis with reduced uptake and β-
oxidation of fatty acids; increased glucose flux, myocardial oxygen
efficiency and glycolytic ATP production; replenishment of citric
acid cycle intermediates via anaplerosis; and activation of prosur-
vival reperfusion injury salvage kinases (RISK) including Akt and
AMPK [7]. GIK has been shown to improve postoperative haemo-
dynamics, decrease inotrope requirements and reduce myocardial
injury in patients undergoing cardiac surgery [6, 7, 22], but has not
Table 3: Study outcomes, the perhexiline group compared with the control group
Outcomes Perhexiline Control Odds ratio (95% CI) P-value
Primary outcome, n (%) 139 147
Low cardiac output episode 51 (36.69%) 51 (34.69%) 0.92 (0.56 to 1.50) 0.74
Secondary outcomes, categorical, n (%) 139 147
Inotrope use in first 6 ha 39 (28.06%) 36 (24.49%) 0.84 (0.49 to 1.44) 0.52
Inotrope use in first 12 h 67 (48.20%) 50 (34.01%) 0.55 (0.34 to 0.89) 0.015
Newmyocardial injury on ECG 23 (16.55%) 25 (17.01%) 1.02 (0.55 to 1.92) 0.94
Secondary outcomes, continuous, mean (SD) 135 144
Cardiac index at 6 h (l/min/m2) 2.51 (0.43) 2.70 (0.54) 0.19 (0.07 to 0.31)b 0.001
Peak troponin-T (ng/ml) 0.78 (0.71) 0.89 (0.92) 0.11 (−0.09 to 0.30)b 0.28
AUC troponin-T (ng h/ml) 3.98 (3.79) 4.71 (5.32) 0.73 (−0.40 to 1.86)b 0.12c
Accounting for baseline left ventricular function and priority of surgery, with surgeon as a random effect.
SD: standard deviation; AUC: area under the concentration-time curve.
aBefore cardiopulmonary bypass, during cardiopulmonary bypass and 0–6 h.
bDifference in means (95% confidence interval).
cOne-tailed.
Table 2: Operative variables
Perhexiline (n = 139) Control (n = 147)
Number of grafts, mean (SD) 3.30 (0.73) 3.29 (0.82)
Internal mammary artery graft used, n (%) 132 (95.0) 136 (92.5)
Additional procedure, n (%) 1 (0.7) 4 (2.7)
Operation performed by trainee, n (%) 38 (27.3)a 50 (34.0)
CPB time, median (IQR) (min) 109 (93–131)b 110 (90–134)
Reinstitution of CPB, n (%) 3 (2.2) 6 (4.1)
Aortic cross-clamp time, median (IQR) (min) 56 (45–70)b 57 (45–72)
Total cardioplegia dose, median (IQR) (l) 1.95 (1.70–2.30) 1.90 (1.62–2.24)
Reperfusion VF/VT, n (%) 3 (2.2) 3 (2.0)
Antifibrinolytic used, n (%) 97 (69.8) 100 (68.0)
Cell salvaged blood, median (IQR) (ml) 470 (260–700) 485 (300–700)
Intra-aortic balloon pump used, n (%) 10 (7.2)a 21 (14.3)
Preop for unstable angina 1 (0.7) 0 (0)
Preop elective in theatre 3 (2.2) 6 (4.1)
Pre-CPB for intraoperative instability 2 (1.4) 0 (0)
During CPB for anticipated instability 1 (0.7) 4 (2.7)
Post-CPB for instability 3 (2.2)a 11 (7.6)
Reinstitution of CPB relates to episodes of unsuccessful weaning from CPB requiring a second period of CPB to prevent cardiovascular collapse.
CPB: cardiopulmonary bypass; VF: ventricular fibrillation; VT: ventricular tachycardia; SD: standard deviation; IQR: interquartile range.
aNot significant with Fisher’s exact test.
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been widely adopted principally due to practical difficulties in its
administration. While perhexiline has not previously been studied
as an adjunct to myocardial protection in cardiac surgery, it has
been shown to be clinically effective in the treatment of refractory
angina [8], chronic cardiac failure [9] and symptomatic hypertrophic
cardiomyopathy [10]. Its mechanism of action has been widely
accepted as inhibition of mitochondrial CPT-1, leading to reduced
uptake and β-oxidation of long-chain fatty acids [12]. A recent
proteomic and metabolomic study in a murine model suggested
that perhexiline activates the pyruvate dehydrogenase complex and
may cause a complex rebalancing of carbon and nucleotide phos-
phate fluxes to increase metabolic flexibility [23]. However, our
metabolomic analysis demonstrates that, in patients with ischaemic
heart disease undergoing cardiac surgery, perhexiline has no signifi-
cant effect on the polar myocardial metabolome with no change in
the intermediates of energy transfer, glycolysis or the citric acid
cycle. This lack of up-regulation in glucose metabolism may
account for the lack of clinical benefit in this trial and suggests that
the mechanism of action of perhexiline in vivo in humans may not
be primarily metabolic. The possibility that perhexiline acts via a
CPT-independent pathway has previously been raised following the
observation that there is a temporal dissociation between its effects
on cardiac efficiency and metabolism in a rat heart model [24].
Recent work has shown that it suppresses expression of thioredoxin-
interacting protein (TXNIP), the key regulator of the antioxidant
thioredoxin system, and increases expression of the energy sensor
AMPK and its downstream effector PGC-1α [25], although the
relevance of these observations remains to be proven. While its
predominant mechanism of action in non-surgical patients
remains unconfirmed, we found neither an improvement in con-
tractility at any time point nor a reduction in myocardial injury fol-
lowing ischaemia–reperfusion.
Patients treated with perhexiline had a lower cardiac index prior
to ischaemia although the mechanisms underlying this finding are
unknown. Despite a weak calcium channel inhibitory effect [11],
perhexiline has not previously been found to be negatively ino-
tropic although none of the previous studies involved anaesthesia
or surgery. Plasma free fatty acids prior to ischaemia were
Figure 3: Area under the concentration–time curve for serum troponin-T
(ng h/ml) (P = 0.12).
Figure 2: Mean cardiac index (l/min/m2) between treatment groups. Error bars
represent 95% confidence intervals (CI) for the mean (P = 0.018 at 6 h).





Postoperative death, n (%) 2 (1.4) 2 (1.4)
Stroke, n (%) 3 (2.2) 1 (0.7)
Neurological, n (%) 18 (12.9) 12 (8.2)
Type I (stroke, TIA) 3 (2.2) 2 (1.4)
Type II (confusion, disorientation) 15 (10.8) 10 (6.8)
Chest tube drainage at 12 h, mean (SD) 701 (498) 704 (448)
Reoperation, n (%) 9 (6.5)a 13 (8.8)
Bleeding 6 (4.3) 11 (7.5)
LCOE/tamponade 1 (0.7) 1 (0.7)
Arrest 2 (1.4) 1 (0.7)
Need for CPB at reoperation 1 (0.7) 1 (0.7)
Arrhythmia, n (%) 55 (39.6)a 66 (44.9)
Atrial fibrillation 53 (38.1) 64 (43.5)
Atrial flutter 2 (1.4) 2 (1.4)
Pneumonia, n (%) 15 (10.8) 14 (9.5)
Tracheostomy, n (%) 4 (2.9) 4 (2.7)
Any pulmonary complication, n (%) 33 (23.7) 34 (23.1)
Creatinine day 4, mean (SD) (mg/dl) 1.08 (0.35) 1.10 (0.45)
Creatinine peak, mean (SD) (mg/dl) 1.34 (0.51) 1.30 (0.54)
AKIN score, n (%)
0 121 (87.1) 126 (85.7)
1 13 (9.4) 16 (10.9)
2 2 (1.4) 0 (0%)
3 3 (2.2) 5 (3.4)
RRT requirement, n (%) 3 (2.2) 2 (1.4)
Abdominal complication, n (%) 5 (3.6) 4 (2.7)
Gastrointestinal bleed 2 (1.4) 2 (1.4)
Prolonged paralytic ileus 0 (0) 2 (1.4)
Diarrhoea 3 (2.2) 0 (0)
Sternal infection, n (%) 5 (3.6) 5 (3.4)
Superficial infection/dehiscence 5 (3.6) 4 (2.7)
Deep infection requiring surgery 0 (0) 1 (0.7)
Any treated infective episode, n (%) 27 (19.4)a 25 (17.0)
Transfusion, mean (SD) (units)
Blood 2.26 (2.62) 2.02 (2.58)
Platelets 0.82 (1.30) 0.85 (1.18)
Fresh frozen plasma 1.89 (2.55) 1.85 (2.64)
Fluid volume in 12 h, mean (SD) (ml/kg) 67.4 (27.5) 62.7 (31.3)
Discharge, n (%) 137 (98.6) 145 (98.6)
Home 130 (93.5) 138 (93.9)
Convalescence 5 (3.6) 6 (4.1)
Another hospital/department 2 (1.4) 1 (0.7)
TIA: transient ischaemic attack; LCOE: low cardiac output episode; CPB:
cardiopulmonary bypass; AKIN: Acute Kidney Injury Network; RRT:
renal replacement therapy; SD: standard deviation.
aNot significant with Fisher’s exact test.
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significantly higher in the perhexiline group than the control
group; high levels of fatty acids are known to reduce cardiac effi-
ciency although there was no correlation between plasma free
fatty acids and preischaemic cardiac index. In the design and
conduct of the trial, randomization was stratified for left ventricular
function, although it was not precisely quantified on echocardio-
gram prior to commencing the trial therapy. All patients in whom
the primary end-point was available were analysed on an
intention-to-treat basis and no differences between groups were
observed for the primary end-point, other secondary outcomes
apart from the cardiac index, safety end-points or any other post-
operative variable.
One of the limitations of perhexiline is the marked interindivi-
dual variation in its metabolism mainly due to genetic poly-
morphisms of CYP2D6 [11]. The dosing regimen used in this trial
attempted to achieve prompt but effective loading with perhexi-
line in the community with a low incidence of toxicity, especially
in poor metabolizers of the drug. We found that 27% of the per-
hexiline group were below the lower threshold of the therapeutic
range (0.15 mg/l) at the time of surgery but there was no correl-
ation with length of therapy, suggesting that the minimum period
of loading was sufficient. These sub-therapeutic patients com-
prised all of those found to be ultrarapid metabolizers of perhexi-
line plus some of the patients who had reported side effects and
were either known or presumed to have stopped taking the drug.
While this failure to attain a therapeutic concentration at the time
of surgery is a limitation of perhexiline use, the comparison of
therapeutic patients with propensity score-matched controls con-
firmed that perhexiline had no benefit in reducing the incidence
of LCOE in this trial.
In conclusion, the addition of oral perhexiline as an adjunct to
cardioplegia in patients undergoing CABG did not improve clinical
or biochemical end-points of myocardial protection or any other
outcome measures, and was associated with a reduction in the
perioperative cardiac index. Therefore, preoperative perhexiline
does not improve the outcomes of patients undergoing cardiac
surgery and may in fact impair cardiac function in the periopera-
tive period, increasing the need for inotropic support. We also
present novel human data suggesting that perhexiline has no sig-
nificant effect on the MS-visible polar myocardial metabolome in
vivo at therapeutic serum concentrations; this supports the sug-
gestion that perhexiline acts via a pathway that is largely or entirely
independent of myocardial CPT-1 inhibition [24] and may explain
the lack of clinical benefit observed following surgery.
SUPPLEMENTARYMATERIAL
Supplementary material is available at EJCTS online.
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